Empfehlungen zur Früherkennung, Risikoreduktion, Überwachung und Therapie bei Patienten mit Lynch-Syndrom

Zusammenfassung

Einleitung Das Lynch-Syndrom (LS) ist die häufigste Form des erblichen Darmkrebses und verursacht ca. 3 % aller kolorektalen Karzinome (KRK). Ursächlich ist eine pathogene Sequenzvariante in einem Mismatch-Reparaturgen (MLH1, MSH2, MSH6, PMS2, EPCAM). Nach aktueller Schätzung ist ca. eine von 300 Personen Anlageträger für LS (ca. 300 000 Mutationsträger/Deutschland). Anlageträger haben ein erhöhtes Lebenszeitrisiko für ein KRK mit einer kumulativen Inzidenz von 15 bis 46 % bis zum 75. Lebensjahr. Weiterhin ist auch das Risiko für extrakolonische Tumoren wie Endometrium-, Dünndarm-, Magen-, Urothel- und andere Karzinome erhöht.

Methoden Das Deutsche Konsortium Familiärer Darmkrebs besteht aus 14 universitären Zentren in Deutschland. Das Ziel des Konsortiums ist es, geeignete Vorsorgeprogramme zu entwickeln und zu evaluieren, damit diese später in die allgemeine Patientenversorgung übernommen werden können. Wir haben aktuell die Empfehlung zur klinischen Betreuung von LS-Patienten überarbeitet.

Ergebnis Eine Koloskopie sollte ab dem 25. Lebensjahr alle 12–24 Monate erfolgen. Bei Diagnose eines KRK ist eine onkologische Resektion notwendig, eine Kolektomie mit ileorektaler Anastomose sollte individuell mit dem Patienten besprochen werden. Das Lebenszeitrisiko für ein Magenkarzinom liegt bei 0,2–13 %. Im Rahmen der endoskopischen Überwachung können signifikant mehr Magenkarzinome in früheren Tumorstadien entdeckt werden im Vergleich zur symptomgetriggerten Endoskopie. Das Lebenszeitrisiko für ein Dünndarmkarzinom liegt bei 4–8 %. Dünndarmkarzinome treten zur Hälfte im Duodenum auf, in 10 % der Fälle vor dem 35. Lebensjahr. Eine ÖGD sollte deshalb ab dem 25. Lebensjahr alle 12–36 Monate erfolgen.

Schlussfolgerung Die Früherkennung, Vorsorge und Behandlung von kolonischen und extrakolonischen Karzinomen bei Patienten mit LS reduziert die Mortalität und Morbidität, ist aber komplex und in verschiedenen Aspekten noch nicht umfassend evaluiert. Weitere gen- und geschlechtsspezifische Vorsorgeempfehlungen sind wünschenswert und sollen in prospektiven Studien evaluiert werden.

Abstract

Introduction Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome and accounts for ~3 % of all CRCs. This autosomal dominant disorder is caused by germline mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM). One in 300 individuals of the general population are considered to be mutation carriers (300 000 individuals/Germany). Mutation carriers are at a high CRC risk of 15–46 % till the age of 75 years. LS also includes a variety of extracolonic malignancies such as endometrial, small bowel, gastric, urothelial, and other cancers.

Methods The German Consortium for Familial Intestinal Cancer consists of 14 university centers in Germany. The aim of the consortium is to develop and evaluate surveillance programs and to further translate the results in clinical care. We have revisited and updated the clinical management guidelines for LS patients in Germany.

Results A surveillance colonoscopy should be performed every 12–24 months starting at the age of 25 years. At diagnosis of first colorectal cancer, an oncological resection is advised, an extended resection (colectomy with ileorectal anastomosis) has to be discussed with the patient. The lifetime risk for gastric cancer is 0.2–13 %. Gastric cancers detected during surveillance have a lower tumor stage compared to symptom-driven detection. The lifetime risk for small bowel cancer is 4–8 %. About half of small bowel cancer is located in the duodenum and occurs before the age of 35 years in 10 % of all cases. Accordingly, patients are advised to undergo an esophagogastroduodenoscopy every 12–36 months starting by the age of 25 years.

Conclusion LS colonic and extracolonic clinical management, surveillance and therapy are complex and several aspects remain unclear. In the future, surveillance and clinical management need to be more tailored to gene and gender. Future prospective trials are needed.

Schlüsselwörter

Darm - kolorektales Adenom - kolorektales Karzinom - Rektumkarzinom - Magen - Magenkarzinom - Magenpolyp

Key words

colorectal cancer - lynch syndrome - hnpcc - gastric cancer - small bowel cancer - hereditary colorectal cancer

• Literatur

• 1 Win AK, Jenkins MA, Dowty JG. et al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiology Biomarkers & Prevention 2017; 26: 404-412
• 2 Latham A, Srinivasan P, Kemel Y. et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology 2018;
• 3 Kather JN, Pearson AT, Halama N. et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine 2019; 25: 1054-1056
• 4 Schmiegel W, Buchberger B, Follmann M. et al. S3-Leitlinie – Kolorektales Karzinom. Z Gastroenterol 2017; 55: 1344-498
• 5 South CD, Hampel H, Comeras I. et al. The Frequency of Muir-Torre Syndrome Among Lynch Syndrome Families. JNCI: Journal of the National Cancer Institute 2008; 100: 277-281
• 6 Mecklin JP, Aarnio M, Laara E. et al. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 2007; 133: 1093-1098
• 7 Vasen HFA, Abdirahman M, Brohet R. et al. One to 2-Year Surveillance Intervals Reduce Risk of Colorectal Cancer in Families With Lynch Syndrome. Gastroenterology 138: 2300-2306
• 8 Engel C, Vasen HF, Seppälä T. et al. No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. Gastroenterology 2018; 155: 1400-1409.e2
• 9 Møller P, Seppälä TT, Bernstein I. et al. Cancer risk and survival inpath_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 2017; 67: 1306-1316
• 10 ten Broeke SW, van der Klift HM, Tops CMJ. et al. Cancer Risks for PMS2-Associated Lynch Syndrome. Journal of Clinical Oncology 2018; 36: 2961-2968
• 11 Tribonias G, Theodoropoulou A, Konstantinidis K. et al. Comparison of standard vs high-definition, wide-angle colonoscopy for polyp detection: a randomized controlled trial. Colorectal Disease 2010; 12: e260-e266
• 12 Syngal S, Brand RE, Church JM. et al. ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. The American journal of gastroenterology 2015; 110: 223-262
• 13 Lecomte T, Cellier C, Meatchi T. et al. Chromoendoscopic Colonoscopy for Detecting Preneoplastic Lesions in Hereditary Nonpolyposis Colorectal Cancer Syndrome. Clinical Gastroenterology and Hepatology 2005; 3: 897-902
• 14 East JE, Suzuki N, Stavrinidis M. et al. Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer. Gut 2008; 57: 65-70
• 15 Huneburg R, Lammert F, Rabe C. et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 2009; 41: 316-322
• 16 Stoffel EM, Turgeon DK, Stockwell DH. et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer prevention research 2008; 1: 470-475
• 17 Rahmi G, Lecomte T, Malka D. et al. Impact of Chromoscopy on Adenoma Detection in Patients With Lynch Syndrome: A Prospective, Multicenter, Blinded, Tandem Colonoscopy Study. The American journal of gastroenterology 2015; 110: 288-298
• 18 Bisschops R, Tejpar S, Willekens H. et al. Virtual chromoendoscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial. Endoscopy 2017; 49: 342-350
• 19 Davies J, Burke D, Olliver JR. et al. Methylene blue but not indigo carmine causes DNA damage to colonocytes in vitro and in vivo at concentrations used in clinical chromoendoscopy. Gut 2007; 56: 155-156
• 20 Jarrar AM, Church JM, Fay S. et al. Is the Phenotype Mixed or Mistaken? Hereditary Nonpolyposis Colorectal Cancer and Hyperplastic Polyposis Syndrome. Diseases of the Colon & Rectum 2009; 52: 1949-1955
• 21 Hamoudah T, Ma K, Esteban M. et al. Patients with small and diminutive proximal hyperplastic polyps have higher rates of synchronous advanced neoplasia compared with patients without serrated lesions. Gastrointestinal endoscopy 2018; 87: 1518-1526
• 22 Bhalla A, Zulfiqar M, Weindel M. et al. Molecular Diagnostics in Colorectal Carcinoma. Clinics in Laboratory Medicine 2013; 33: 835-859
• 23 Ahadova A, Gallon R, Gebert J. et al. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. International Journal of Cancer 2018; 143: 139-150
• 24 Møller P, Seppälä T, Bernstein I. et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 2015; 66: 464-472
• 25 Engel C, Rahner N, Schulmann K. et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2010; 8: 174-182
• 26 Liljegren A, Barker G, Elliott F. et al. Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008; 26: 3434-3439
• 27 van Rijn JC, Reitsma JB, Stoker J. et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. The American journal of gastroenterology 2006; 101: 343-350
• 28 Iino H, Simms L, Young J. et al. DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut 2000; 47: 37-42
• 29 Rijcken FEM, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut 2002; 50: 382-386
• 30 Lim EJ, Leung C, Pitman A. et al. Magnetic resonance colonography for colorectal cancer screening in patients with Lynch syndrome gene mutation. Familial cancer 2010; 9: 555-561
• 31 Vleugels JLA, Sahin H, Hazewinkel Y. et al. Endoscopic detection rate of sessile serrated lesions in Lynch syndrome patients is comparable with an age- and gender-matched control population: case-control study with expert pathology review. Gastrointestinal endoscopy 2018; 87: 1289-1296
• 32 Edelstein DL, Axilbund J, Baxter M. et al. Rapid Development of Colorectal Neoplasia in Patients with Lynch Syndrome. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2011; 9: 340-343
• 33 Rondagh EJA, Gulikers S, Gómez-García EB. et al. Nonpolypoid colorectal neoplasms: a challenge in endoscopic surveillance of patients with Lynch syndrome. Endoscopy 2013; 45: 257-264
• 34 Watanabe T, Muto T, Sawada T. et al. Flat adenoma as a precursor of colorectal carcinoma in hereditary nonpolyposis colorectal carcinoma. Cancer 1996; 77: 627-634
• 35 Zhao S, Wang S, Pan P. et al. Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterology 2019; 156: 1661-1674.e11
• 36 Meining A, Schmidbaur W, Schumacher B. et al. Neufassung der Standard-Terminologie in der gastroenterologischen Endoskopie – Ergebnis eines Konsensusprojekts der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol 2018; 56: e1
• 37 Renkonen-Sinisalo L, Kivisaari A, Kivisaari L. et al. Utility of computed tomographic colonography in surveillance for hereditary nonpolyposis colorectal cancer syndrome. Familial cancer 2007; 6: 135-140
• 38 Parry S, Win AK, Parry B. et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers – the advantage of more extensive colon surgery. Gut 2011;
• 39 Schulmann K, Engel C, Propping P. et al. Small bowel cancer risk in Lynch syndrome. Gut 2008; 57: 1629-1630
• 40 Capelle LG, Van Grieken NC, Lingsma HF. et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010; 138: 487-492
• 41 Engel C, Loeffler M, Steinke V. et al. Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome. Journal of Clinical Oncology 2012; 30: 4409-4415
• 42 Renkonen-Sinisalo L, Sipponen P, Aarnio M. et al. No Support for Endoscopic Surveillance for Gastric Cancer in Hereditary Non-Polyposis Colorectal Cancer. Scandinavian Journal of Gastroenterology 2002; 37: 574-577
• 43 Aarnio M, Salovaara R, Aaltonen LA. et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. International Journal of Cancer 1997; 74: 551-555
• 44 Ladigan S, Vangala D, Pox C. et al. Value of EGD for gastric cancer surveillance in patients with hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome (LS). J Clin Oncol 36, 2018 (suppl; abstr 1522)
• 45 Vasen HFA, Blanco I, Aktan-Collan K. et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62: 812-823
• 46 Fischbach W, Fischbach W, Malfertheiner P. et al. S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 2016; 54: 1
• 47 ten Kate GL, Kleibeuker JH, Nagengast FM. et al. Is surveillance of the small bowel indicated for Lynch syndrome families?. Gut 2007; 56: 1198-1201
• 48 Schulmann K, Brasch FE, Kunstmann E. et al. HNPCC-associated small bowel cancer: Clinical and molecular characteristics. Gastroenterology 2005; 128: 590-599
• 49 Basford PJ, Bhandari P. Endoscopic management of nonampullary duodenal polyps. Therapeutic Advances in Gastroenterology 2012; 5: 127-138
• 50 Hammoudi N, Dhooge M, Coriat R. et al. Duodenal tumor risk in Lynch syndrome. Digestive and Liver Disease 2019; 51: 299-303
• 51 Vangala D, Pox C, Ladigan S. et al. Clinical characteristics and EGD surveillance in Lynch-syndrome patients with small bowel/duodenal carcinomas. J Clin Oncol 36, 2018 (suppl; abstr 1555)
• 52 Saurin JC, Pilleul F, Soussan EB. et al. Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome. Endoscopy 2010; 42: 1057-1062
• 53 Haanstra JF, Al-Toma A, Dekker E. et al. Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Gut 2015; 64: 1578-1583
• 54 Haanstra JF, Al-Toma A, Dekker E. et al. Incidence of small bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Endosc Int Open 2017; 5: E622-E626
• 55 Kastrinos F, Mukherjee B, Tayob N. et al. RIsk of pancreatic cancer in families with lynch syndrome. JAMA 2009; 302: 1790-1795
• 56 Canto MI, Harinck F, Hruban RH. et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347
• 57 Dove-Edwin I, de Jong AE, Adams J. et al. Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without Lynch syndrome. Gastroenterology 2006; 130: 1995-2000
• 58 Rijcken FEM, Mourits MJE, Kleibeuker JH. et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecologic Oncology 2003; 91: 74-80
• 59 Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstetricia et Gynecologica Scandinavica 2011; 90: 437-444
• 60 Renkonen-Sinisalo L, Bützow R, Leminen A. et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. International Journal of Cancer 2007; 120: 821-824
• 61 Lecuru F, Le Frere Belda MA, Bats AS. et al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 2008; 18: 1326-1331
• 62 Manchanda R, Menon U, Michaelson-Cohen R. et al. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Current Opinion in Obstetrics and Gynecology 2009; 21: 31-38
• 63 Helder-Woolderink JM, De Bock GH, Sijmons RH. et al. The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome. Gynecologic Oncology 2013; 131: 304-308
• 64 Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985; 56: 403-412
• 65 (DGGG) DGfGuG. S3 Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom. 2018
• 66 Schmeler KM, Lynch HT, Chen LM. et al. Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome. New England Journal of Medicine 2006; 354: 261-269
• 67 Etchegary H, Dicks E, Watkins K. et al. Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers. Hereditary cancer in clinical practice 2015; 13: 10
• 68 Harkness EF, Barrow E, Newton K. et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. Journal of Medical Genetics 2015; 52: 553-536
• 69 Barrow PJ, Ingham S, O’Hara C. et al. The spectrum of urological malignancy in Lynch syndrome. Familial cancer 2013; 12: 57-63
• 70 Barrow E, Robinson L, Alduaij W. et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics 2009; 75: 141-149
• 71 Myrhøj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Familial cancer 2008; 7: 303-307
• 72 Messer J, Shariat SF, Brien JC. et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU International 2011; 108: 701-705
• 73 Reynolds JP, Voss JS, Kipp BR. et al. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples. Cancer Cytopathology 2014; 122: 459-467
• 74 Jinzaki M, Matsumoto K, Kikuchi E. et al. Comparison of CT Urography and Excretory Urography in the Detection and Localization of Urothelial Carcinoma of the Upper Urinary Tract. American Journal of Roentgenology 2011; 196: 1102-1109
• 75 Winkels RM, Botma A, Van Duijnhoven FJB. et al. Smoking Increases the Risk for Colorectal Adenomas in Patients With Lynch Syndrome. Gastroenterology 2012; 142: 241-247
• 76 Botma A, Nagengast FM, Braem MGM. et al. Body Mass Index Increases Risk of Colorectal Adenomas in Men With Lynch Syndrome: The GEOLynch Cohort Study. Journal of Clinical Oncology 2010; 28: 4346-4353
• 77 Burn J, Gerdes AM, Macrae F. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet 2011; 378: 2081-2087
• 78 Rothwell PM, Fowkes FGR, Belch JFF. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. The Lancet 2011; 377: 31-41
• 79 Barrow P, Khan M, Lalloo F. et al. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. The British journal of surgery 2013; 100: 1719-1731